MEDBOT-B (02252) rose more than 3%, with a gain of 2.7% to HK$35.04 at the time of writing. The turnover was HK$148 million. On the news front, during the recent 93rd China International Medical Equipment Fair (CMEF), Han Xiaolu, Overseas Sales Director of MEDBOT, revealed in an interview that the pace of new orders from the company's international markets is accelerating rapidly. Compared to the same period last year, the sales revenue from new overseas orders in 2026 has increased by over 400% year-on-year. Furthermore, Han Xiaolu noted that in key European markets, MEDBOT is one of the few domestic brands to have achieved genuine commercial installation of its systems, successfully entering high-end medical hubs such as Belgium, the UK, France, and Spain. As of early April 2026, the company had installed 23 units of its Toumai laparoscopic surgical robot, with a backlog of 86 units. Management guidance indicates installations of approximately 103-113 units in the first half of 2026 and at least 200 units for the full year, signaling that previous delivery bottlenecks have been resolved. The overseas market remains a core growth engine for the company, covering regions including South America, Asia, and Europe.